A randomised study comparing carboplatin and carboplatin with thalidomide in patients with Stage Ic-IV Ovarian Cancer

Completed

• Conditions: Ovarian cancer; Cancer

• Registration Number: ISRCTN12694440
• Lead Sponsor: Cancer Research UK (CRUK) (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2002-08-19
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

1. Histologically confirmed epithelial ovarian cancer
2. Post-menopausal or if pre-menopausal, patients must have had a bilateral salpingo-oophorectomy and/or a total abdominal hysterectomy
3. Stage Ic-IV ovarian cancer
4. Aged over 18 years
5. World Health Organisation (WHO) performance status 0, 1 or 2
6. Written informed consent
7. No previous carboplatin/cisplatin treatment for ovarian cancer
8. No other current invasive malignancy
9. Neither pregnant or with the ability to become pregnant
10. No chronic neurological disease causing peripheral neuropathy
11. No diabetes mellitus

Exclusion Criteria

Not provided at time of registration

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Safety <br>2. Response <br>3. Markers of angiogenesis

Secondary Outcome Measures

Name	Time	Method
o secondary outcome measures